drugset / Trial / NCT04889391
Study of Radiolabeled Danicopan in Healthy Male Participants
Phase 1
Completed
8 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
NaSingle-groupOpen-labelBasic science
Summary
This was an open-label study to evaluate the absorption, distribution, metabolism, and excretion of radioactivity in healthy male participants following a single 150-milligram (mg) oral dose of carbon-14 (\[14C\])-ACH-014447 (\[14C\])-danicopan) containing approximately 100 microcuries (µCi) of \[14C\].
Timeline
- Start
- 2017-09-14
- Primary completion
- 2017-10-15
- Completion
- 2017-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danicopan | Small molecule | 150 mg | Oral |
Indications
No indication recorded.